Keyphrases
Clinical Outcomes
100%
Clinical Trials
100%
Endometrial Cancer
100%
Monotherapy
100%
Microsatellite Stable
100%
Immunotherapy Trials
100%
Combination Immunotherapy
100%
Immunotherapy Therapy
100%
Overall Survival
50%
Progression-free Survival
50%
MD Anderson Cancer Center
25%
Cancer Patients
25%
Clinical Benefit
25%
Partial Response
25%
Poor Response
25%
Radiological Response
25%
Conventional Therapy
25%
Line of Therapy
25%
RECIST 1.1
25%
Immune Checkpoint
25%
Immune Checkpoint Inhibitors
25%
Medicine and Dentistry
Immunotherapy
100%
Uterine Cancer
100%
Immunotherapy Clinical Trial
100%
Monotherapy
33%
Overall Survival
16%
Progression Free Survival
16%
Malignant Neoplasm
8%
Retrospective Study
8%
Clinical Trial
8%
Immunity
8%
Immune Checkpoint Inhibitor
8%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Endometrium Cancer
100%
Immunotherapy Clinical Trial
100%
Monotherapy
33%
Overall Survival
16%
Progression Free Survival
16%
Retrospective Study
8%
Malignant Neoplasm
8%
Clinical Trial
8%
Immune Checkpoint Inhibitor
8%